Cabozantinib and Pembrolizumab in Metastatic Pancreas
Purpose
This study aims to evaluate cabozantinib and pembrolizumab for the treatment of metastatic pancreatic adenocarcinoma.
Condition
- Pancreatic Cancer
Eligibility
- Eligible Ages
- Between 18 Years and 99 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Diagnosis of pancreatic ductal adenocarcinoma - Evidence of progression or intolerance to previous standard of care pancreatic cancer systemic or locoregional therapies - Patients must have adequate organ function
Exclusion Criteria
- Chemotherapy or other locoregional anti-tumoral therapies performed within 28 days of study treatment initiation - Received palliative radiation therapy within 2 weeks or any other radiation therapy within 4 weeks of start of study intervention - Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to allocation - Has a diagnosis of immunodeficiency (autoimmune disease) or is receiving chronic systemic steroid therapy - Clinically significant cardiovascular disease - Uncontrolled hypertension - Inability to swallow tablets
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- N/A
- Intervention Model
- Single Group Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental Cabozantinib and pembrolizumab |
|
Recruiting Locations
More Details
- NCT ID
- NCT05052723
- Status
- Completed
- Sponsor
- Joseph Kim